Biosimilars: a great opportunity for pharmacists in England

by Jonathan Campbell, RPS Regional Liaison Pharmacist

Biosimilars have huge benefits for patients and the NHS and offer opportunities for pharmacists too.

The NHS Long Term Plan sets out how “the NHS will move to a new service model in which patients get more options, better support, and properly joined-up care at the right time in the optimal care setting”.

These new models of integrated care will need organisations and their staff to work together across the traditional boundaries of community, general practice and hospital – adopting a system leadership approach to improving population health that puts the patient at its heart. Read more Biosimilars: a great opportunity for pharmacists in England

Biologics and biosimilars – what are they?

By Jayne Lawrence, Head of Division of Pharmacy and Optometry, University of Manchester.

The Commissioning Framework for Biological Medicines announced recently by NHS England will both help guide improvements to developing better medicines for patients and provide a guide to ensuring the NHS gets best value for money from these innovative, exciting medicines.

What is a biologic?
Biological medicines have made many new, groundbreaking treatments possible, significantly improving the lives of many patients with long term conditions such as diabetes, arthritis, anaemia associated with chronic kidney failure, and types of cancer.

They are extremely expensive, in part due to the complexity of their production. For example, a course of a new immunotherapy drug typically costs more than £100,000 per patient per year. Furthermore, as biologicals currently comprise approximately 50% of all new drug approvals, it is likely that the high cost of new medicines is with us for the foreseeable future. Consequently, any way of reducing the cost of these important medicines is vital. Read more Biologics and biosimilars – what are they?